[1] J. Ferlay et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” Int. J. cancer, vol. 136, no. 5, pp. E359–E386, 2015.
[2] H. Sung et al., “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., 2021.
[3] K. M-amen et al., “Cancer Incidence in the Kurdistan Region of Iraq: Results of a Seven-Year Cancer Registration in Erbil and Duhok Governorates.,” Asian Pacific J. Cancer Prev. APJCP, vol. 23, no. 2, pp. 601–615, 2022.
[4] T. Foukakis and J. Bergh, “Prognostic and predictive factors in early, non-metastatic breast cancer,” Dizon Ed UpToDate, 2016.
[5] S. Nimesh, N. Gupta, and R. Chandra, “Nanomedicine for the treatment of breast cancer,” in Post-genomic Approaches in Cancer and Nano Medicine, River Publishers, pp. 267–285, 2022.
[6] R. Yadav, R. Sen, and P. Chauhan, “Calculation of NPI score: prognosis of breast cancer,” Exec. Ed., vol. 4, no. 4, p. 205, 2013.
[7] E. Gray, A. Donten, K. Payne, and P. S. Hall, “Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies,” Syst. Rev., vol. 7, no. 1, pp. 1–9, 2018.
[8] A. H. S. Lee and I. O. Ellis, “The Nottingham prognostic index for invasive carcinoma of the breast,” Pathol. Oncol. Res., vol. 14, pp. 113–115, 2008.
[9] J. GARNER, “In the case of breast cancer, how can these be combined to give prognostic information?,” Quest. MRCS vivas. London Arnold, p. 231, 2004.
[10] P. A. Fasching et al., “Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment,” BMC Cancer, vol. 11, no. 1, pp. 1–13, 2011.
[11] P. Gong, Y. Wang, G. Liu, J. Zhang, and Z. Wang, “New insight into Ki67 expression at the invasive front in breast cancer,” PLoS One, vol. 8, no. 1, p. e54912, 2013.
[12] S. C. Prabhu, “A study on Nottingham prognostic index and its correlation with ER , PR , HER-2 / NEU and KI-67 in breast carcinomas,” vol. 8, no. 2, pp. 188–192, 2021.
[13] V. Özmen, T. Özmen, and V. Doğru, “Breast cancer in Turkey; an analysis of 20.000 patients with breast cancer,” Eur. J. breast Heal., vol. 15, no. 3, p. 141, 2019.
[14] H. Abdel-Razeq et al., “Late presentation and suboptimal treatment of breast cancer among Syrian refugees: a retrospective study,” J. Int. Med. Res., vol. 49, no. 5, p. 03000605211018448, 2021.
[15] M. H. Amer, “Genetic factors and breast cancer laterality,” Cancer Manag. Res., pp. 191–203, 2014.
[16] R. F. Neri A, Marrelli D, Megha T, Bettarini F, Tacchini D, De Franco L, “Clinical significance of multifocal and multicentric breast cancers and choice of surgical treatment: a retrospective study on a series of 1158 cases,” BMC Surg., vol. 15, no. 1, pp. 1–10, 2015.
[17] J. R. Bundred et al., “Margin status and survival outcomes after breast cancer conservation surgery: Prospectively registered systematic review and meta-analysis,” bmj, vol. 378, 2022.
[18] U. Güth, H. Moch, L. Herberich, and W. Holzgreve, “Noninflammatory breast carcinoma with skin involvement: clinical diagnosis is relevant to appropriate classification in the TNM system,” Cancer, vol. 100, no. 3, pp. 470–478, 2004.
[19] A. Tevfik, H. Yabanoğlu, M. Erkent, P. Börcek, and K. U. Ş. Murat, “Paget’s Disease Of The Breast: Clinical-Pathological Findings And Surveillance,” Çukurova Anestezi ve Cerrahi Bilim. Derg., vol. 3, no. 3, pp. 230–238, 2020.
[20] P. Narayan et al., “Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer,” Sci. Rep., vol. 11, no. 1, p. 12781, 2021.
[21] S. Sadiq, U. Rihan, B. Parveen, J. Ahsan, A. Shafiq, and S. Shaukat, “Ki-67 EXPRESSION STATUS IN INVASIVE CARCINOMAS OF BREAST: A CO-RELATION WITH CLINICO-PATHOLOGIC AND PROGNOSTIC PARAMETERS,” Asian J. Allied Heal. Sci., vol. 7, no. 2, 2022.
[22] A. Zaimi, S. A. Brahmi, and S. Afqir, “Nottingham prognostic index is an applicable prognostic tool in non-metastatic triple-negative breast cancer,” Asian Pacific J. cancer Prev. APJCP, vol. 20, no. 1, p. 59, 2019.
[23] A. Pradhan, P. Paudyal, A. K. Sinha, and C. S. Agrawal, “Grading, staging and Nottingham prognostic index scoring of breast carcinoma,” J. Pathol. Nepal, vol. 7, no. 1, pp. 1078–1083, 2017.
[24] Z. Ahmad, A. Khurshid, A. Qureshi, R. Idress, N. Asghar, and N. Kayani, “Breast carcinoma grading, estimation of tumor size, axillary lymph node status, staging, and nottingham prognostic index scoring on mastectomy specimens,” Indian J. Pathol. Microbiol., vol. 52, no. 4, p. 477, 2009.
[25] K. Gite and R. Chaudhari, “Histopathological Evaluation of Carcinoma Breast with Significance of Histological Grading and other Morphological Prognostic Factors at a Tertiary Health Care Institute,” MVP J. Med. Sci., pp. 185–193, 2018.
[26] F. K. S. NIAZI and A. RABIA BASHARAT, “Role of Nottingham Prognostic Index Scoring in Determining Prognosis of Breast Carcinoma in Different Age Groups,” J. Fatima Jinnah Med. Univ., vol. 10, no. 1, 2016.
[27] Z. M. Akhtar, R. Altaf, M. S. Amin, and S. Butt, “Relationship of Nottingham Prognostic Index with prognostic parameters of breast carcinoma,” Pakistan J. Med. Heal. Sci., vol. 16, no. 06, p. 26, 2022.